Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
← catalyst calendarNCT07044336 · readout in 422 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
800estimated
Sites
320
Countries
Argentina, Australia, Austria +25
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-01 | actual | When the study began enrolling |
| Primary completion | 2027-10-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Endometrial Cancer
- Malignant Solid Tumour
Interventions
- Drug: Puxitatug Samrotecan — also filed as Puxi-Sam
- Drug: Doxorubicin — also filed as ADRIAMYCIN®
- Drug: Paclitaxel — also filed as TAXOL®
Primary outcomes
what the primary-completion date above is the date OFProgression Free Survival (PFS) for Arm A vs Arm B
measured Approximately 3 years
Overall survival (OS) for Arm A vs Arm B
measured Approximately 3 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed